The latest biotech news

Screenshot 2016 12 08 at 5.09.55 PM e1481213471552

News and Trends 9 Dec 2016

Paris takes the lead in Digital Health for Diabetes Type 2

The smell of freshly baked baguettes and good news from the capital have brought us this week to France. Voluntis has received market approval for a device that could change the life of millions of people with diabetes type 2, check out this cool company! City: Paris, France Founded: 2001 Employees: 100 Financial data: Total of €29.8M raised in […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Galapagos gets another Milestone Payment from Gilead

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […]

December 9, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 12 08 at 4.52.00 PM e1481212500410

News and Trends 9 Dec 2016

Our Startup Battle Winner uses CRISPR in a Whole New Way

Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […]

December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Lifting the Chemo Fog: Virtual Reality has Medical Applications!

Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […]

December 9, 2016 - 3 minutesmins - By Ekaterina Perets

News and Trends 8 Dec 2016

Meet the Newest ALS Pioneer Company from Switzerland

AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […]

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2016

The Munich Biotech Mafia expand to the US with a New TCR Startup

TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […]

December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2016

UPDATE: No Clear Winner in the CRISPR Patent Battle

Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win the rights to exploit a technology that could be used to cure any genetic disease? CRISPR has been hailed as the ‘scientific discovery of the […]

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 07 at 4.24.41 PM e1481190128909

News and Trends 8 Dec 2016

Video: How is European Biotech changing the World?

We had the amazing opportunity to hear an overview of biotech in Europe at Labiotech Refresh from Philippe Pouletty, co-founder and managing director of Truffle Capital. Philippe has an incredibly extensive experience in biotech as a founder of multiple companies and VCs. He witnessed how biotech got big over the years with the first innovations coming […]

December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […]

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2016

Ask the Biotech Recruiter: Here are 7 Signs it’s Time to Talk to the Headhunters

Finding a new executive is never easy. Is it time to ask for help? The biotech headhunters at Pact & Partners can lend a hand! How long have you been looking to fill a top-level position at your company? Is it taking more time than expected, and are you stuck scratching your head? Are you […]

December 7, 2016 - 6 minutesmins - By External Contributor

News and Trends 7 Dec 2016

UPDATE: More Good News on a Cannabis Derivative for Epilepsy

Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published on 27/09/2016 GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of […]

December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Paris takes the lead in Digital Health for Diabetes Type 2

Galapagos gets another Milestone Payment from Gilead

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Our Startup Battle Winner uses CRISPR in a Whole New Way

Lifting the Chemo Fog: Virtual Reality has Medical Applications!

Meet the Newest ALS Pioneer Company from Switzerland

The Munich Biotech Mafia expand to the US with a New TCR Startup

UPDATE: No Clear Winner in the CRISPR Patent Battle

Video: How is European Biotech changing the World?

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Ask the Biotech Recruiter: Here are 7 Signs it’s Time to Talk to the Headhunters

UPDATE: More Good News on a Cannabis Derivative for Epilepsy

Subscribe to our newsletter to get the latest biotech news!